Quarterly report pursuant to Section 13 or 15(d)

Revenues - Percentage by Customer (Details)

v3.21.1
Revenues - Percentage by Customer (Details)
3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Grifols | fostamatinib    
Disaggregation of Revenue [Line Items]    
Expected rollout term 18 months  
Sales | Customer concentration risk | Lilly    
Disaggregation of Revenue [Line Items]    
Percentage 78.00%  
Sales | Customer concentration risk | Grifols    
Disaggregation of Revenue [Line Items]    
Percentage   77.00%
Sales | Customer concentration risk | ASD Healthcare and Oncology Supply    
Disaggregation of Revenue [Line Items]    
Percentage   12.00%